Clinical trial
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
NCT00968968
Study timeline
Study start (actual)2010-01-20Date precision: day
Registry last updated2019-06-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Cancerunresolved
Interventions
LapatinibDRUG · verified · RxNorm: lapatinib
TrastuzumabBIOLOGICAL
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
Las VegasNevada, United States3PeoriaIllinois, United States3BostonMassachusetts, United States2San AntonioTexas, United States2SeattleWashington, United States2Salt Lake CityUtah, United States2La JollaCalifornia, United States2RaleighNorth Carolina, United States2Fort WorthTexas, United States2AugustaGeorgia, United States2El PasoTexas, United States2PlanoTexas, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00968968 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.